Almitrine

Almitrine
	File:Almitrine structure.svg
Clinical data
AHFS/Drugs.com	International Drug Names
ATC code	R07AB07 (WHO) ;
Identifiers
	IUPAC name 6-[4-[bis(4-fluorophenyl)methyl]piperazin-1-yl]-N,N'-; diprop-2-enyl-1,3,5-triazine-2,4-diamine;
CAS Number	27469-53-0 ;
PubChem CID	33887;
DrugBank	DB01430 ;
ChemSpider	31235 ;
UNII	9A1222NBG4;
KEGG	D07126 ;
ChEBI	CHEBI:53778 ;
ChEMBL	ChEMBL1183717 ;
E number	{{#property:P628}}
ECHA InfoCard	{{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value).
Chemical and physical data
Formula	C26H29F2N7
Molar mass	477.552 g/mol
3D model (JSmol)	Interactive image;
Melting point	181 °C (357.8 °F)
	SMILES Fc1ccc(cc1)C(c2ccc(F)cc2)N4CCN(c3nc(nc(n3)NC\C=C)NC\C=C)CC4;
	InChI InChI=1S/C26H29F2N7/c1-3-13-29-24-31-25(30-14-4-2)33-26(32-24)35-17-15-34(16-18-35)23(19-5-9-21(27)10-6-19)20-7-11-22(28)12-8-20/h3-12,23H,1-2,13-18H2,(H2,29,30,31,32,33) ; Key:OBDOVFRMEYHSQB-UHFFFAOYSA-N ;
(what is this?) (verify)

Almitrine (marketed as Duxil by Servier) is a diphenylmethylpiperazine derivative classified as a respiratory stimulant by the ATC. It enhances respiration by acting as an agonist of peripheral chemoreceptors located on the carotid bodies. The drug increases arterial oxygen tension while decreasing arterial carbon dioxide tension in patients with chronic obstructive pulmonary disease. It may also prove useful in the treatment of nocturnal oxygen desaturation without impairing the quality of sleep. A significant literature exists for this compound, including over 60 papers that Medline labels as reviews.

The clinical efficacy of almitrine-raubasine combination therapy for age related cerebral disorders and functional rehabilitation after stroke has been reviewed by Allain and Bentué-Ferrer.^[1] They summarize two studies in which almitrine-raubasine improved some symptoms significantly more than placebo, especially in vascular cases. Their paper also suggests that other studies have shown a beneficial effect of this compound on neurosensory vascular disorders, specifically chorioretinal dysfunctions (visual symptomatology) and vertigo associated with electronystagmographic modifications. This paper further claims that the dosage and tolerance of the compound have been confirmed in a French multi-center study of 5,361 outpatients.

References

↑ Allain, H.; Bentué-Ferrer, D. (1998). "Clinical Efficacy of Almitrine-Raubasine". European Neurology. 39 (Suppl. 1): 39–44. doi:10.1159/000052069. PMID 9516074.

Template:Respiratory stimulants Template:Piperazines

Template:Respiratory-system-drug-stub

[1] Allain, H.; Bentué-Ferrer, D. (1998). "Clinical Efficacy of Almitrine-Raubasine". European Neurology. 39 (Suppl. 1): 39–44. doi:10.1159/000052069. PMID 9516074.

[1]

Almitrine

See also

References

Navigation menu